Enlaza Therapeutics
PrivateLast Round
Strategic
Sep 2, 2025
Total Funding Raised
$161M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Enlaza Therapeutics is a biotechnology company that develops covalent protein therapeutics using its proprietary War-Lock platform to create highly selective biologic drugs for cancer and other serious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Enlaza Therapeutics Comparables
Compare Enlaza Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Matchpoint Therapeutics | 78% | |
| BridGene Biosciences | 74% | |
| Nexo Therapeutics | 73% |
Enlaza Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Sep 2, 2025 | ||||
| Series A | Apr 30, 2024 | ||||
| Seed | Dec 15, 2022 |
Enlaza Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| A. M. Pappas & Associates | Series A |
| J.P. Morgan Private Capital | Series A |
| Frazier Life Sciences | Seed, Series A |
| Avalon Ventures | Series A, Seed |
| Amgen Ventures | Series A |
| Samantha | Series A |
| Alexandria Venture Investments | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 100% MoM, reaching 1.9K.
- Sep 2, 2025
$15M raised in early funding.
Enlaza Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Enlaza Therapeutics's valuation, stock price, and market status.
Is Enlaza Therapeutics a public or private company?
Enlaza Therapeutics is a private company.
What is the current stock price of Enlaza Therapeutics?
Enlaza Therapeutics is a private company, so its shares have no public market price. Caplight tracks Enlaza Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Enlaza Therapeutics worth (valuation)?
Valuation information for Enlaza Therapeutics is not publicly available.
Can I buy Enlaza Therapeutics stock?
Enlaza Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Enlaza Therapeutics's last funding round?
Enlaza Therapeutics's most recent funding round was Strategic on September 2, 2025.
Who are the main investors in Enlaza Therapeutics?
Key investors in Enlaza Therapeutics include J.P. Morgan Private Capital, Avalon Ventures, J.P. Morgan Asset Management, J.P. Morgan Life Sciences Private Capital.
Will Enlaza Therapeutics IPO soon?
No public IPO plans have been announced for Enlaza Therapeutics.
How can I track Enlaza Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Enlaza Therapeutics's shares on secondary markets.